Pyridostigmine Alternatives Compared
| Pyridostigmine | Soliris | Vyvgart |
|
|---|
| Pyridostigmine | Soliris (eculizumab) | Vyvgart (efgartigimod alfa) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Myasthenia Gravis, Dysautonomia, Reversal of Nondepolarizing Muscle Relaxants, Nerve Agent Pretreatment. pyridostigmine may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Hemolytic Uremic Syndrome, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Soliris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Myasthenia Gravis. Vyvgart may also be used for purposes not listed in this medication guide. |
Related suggestions Myasthenia Gravis
Popular comparisons
|
|||||||||||||||||||||||
| More about Pyridostigmine | More about Soliris (eculizumab) | More about Vyvgart (efgartigimod alfa) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Pyridostigmine has an average rating of 7.0 out of 10 from a total of 57 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 20% reported a negative effect. |
Soliris has an average rating of 6.0 out of 10 from a total of 3 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Vyvgart has an average rating of 8.4 out of 10 from a total of 12 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 8% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: pyridostigmine side effects in more detail. |
See also: Soliris side effects in more detail. |
See also: Vyvgart side effects in more detail. |
||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all pyridostigmine prices |
View all Soliris prices |
View all Vyvgart prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Mestinon, Mestinon Timespan, Regonol | Other eculizumab brands include: Bkemv, Epysqli |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
354 hours |
120 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 76 drugs are known to interact with pyridostigmine:
|
A total of 65 drugs are known to interact with Soliris:
|
A total of 277 drugs are known to interact with Vyvgart:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 06, 1955 |
March 16, 2007 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.